Eli Lilly Reports Stellar Q1 Performance

On Thursday, Eli Lilly announced a remarkable 45% increase in revenue for the first quarter of fiscal 2025, reaching $12.73 billion. This surge was primarily driven by the exceptional volume growth of its flagship products, Mounjaro and Zepbound.

Financial Highlights and Future Plans

The company posted a net income of $2.76 billion, marking a 23% rise compared to the previous year. Despite facing $1.57 billion in acquired in-process R&D charges, earnings per share stood strong at $3.06. CEO David Ricks shared optimistic insights about the company's oral GLP-1 candidate, forgilzumab, and reiterated the revenue guidance for the year to be between $58 billion and $61 billion. Additionally, Eli Lilly unveiled ambitious plans for a $50 billion expansion in US manufacturing capabilities to cater to the escalating demand.